Pharmaceutical High-Impact Articles on GLP-1

High-Impact articles from Pharmaceutical Journals

Read this high-impact research about GLP-1

From three of the most respected pharmaceutical journals publishing today, Journal of the American Pharmacists Association, JAPhA Practice Innovations, and JAPhA Pharmacotherapy, we’re presenting this high-impact series of research articles about GLP-1.

• Operational and financial implications of GLP-1 agonist reimbursement among independent community pharmaciesopens in new tab/window

• An analysis of national news coverage of semaglutide for weight loss opens in new tab/window

• Semaglutide for obesity management: A narrative review of efficacy, safety, and future directionsopens in new tab/window

• TikTok’s take on adverse effects for glucagon-like peptide-1 and gastric inhibitory polypeptide receptor agonists opens in new tab/window

• Tirzepatide associated autoimmune encephalitis: A case report opens in new tab/window

• Megestrol acetate as an overlooked cause of hyperglycemia in end-stage renal disease: A case of polypharmacyopens in new tab/window

• Increasing SGLT-2 inhibitor prescribing through an integrated case-finding algorithm-guided interdisciplinary intervention opens in new tab/window

• Pharmacist-initiated interventions using RxChange message communication with prescribers for electronic prescriptions: A retrospective descriptive study opens in new tab/window

• Achievement of time in range goals among patients with diabetes using continuous glucose monitoring opens in new tab/window

• TikTokfluence: The rise of GLP-1 receptor agonists in the age of social media health trendsopens in new tab/window

• A cross-sectional study of prescribing rates for SGLT2 inhibitors and GLP-1 receptor agonists among primary care clinics with and without embedded pharmacists opens in new tab/window

• New onset diabetic retinopathy with glucagon-like peptide-1 receptor agonists: A case reportopens in new tab/window

• Semaglutide use in a patient with a long-term ileostomy: A case report highlighting clinical risks and evidence gapsopens in new tab/window

• Medication adherence and persistence of newly initiated medications in older adults with diabetesopens in new tab/window

• Evaluation of clinical decision support to improve guideline directed medical therapy in patients with type 2 diabetes opens in new tab/window

• Use of glucagon-like peptide 1 receptor agonist to sustain patients off basal-bolus insulin regimensopens in new tab/window

• Implementation and evaluation of a pharmacist-led glucagon-like peptide-1 receptor agonist titration service in two primary care clinics opens in new tab/window

• Clinical impact of GLP-1 and GIP/GLP-1 agonist access barriers in primary careopens in new tab/window

• Efficacy of GLP-1 agonists vs. other weight management medications in obese and overweight patientsopens in new tab/window

• Comparison of discharges and graduations for a diverse patient population with socioeconomic barriers from a pharmacist-managed diabetes program opens in new tab/window

• Impact of a pharmacist-led weight management service in patients with metabolic dysfunction–associated steatotic liver disease at outpatient clinics on the United States–Mexico borderopens in new tab/window

• Blood pressure reduction in glucagon-like peptide-1 receptor agonist users in a family medicine clinicopens in new tab/window

• Deprescribing sulfonylureas in patients over the age of 65 within the Boise VA Medical Centeropens in new tab/window

• Review of student pharmacist-led patient assistance program services at a student-run free medical clinicopens in new tab/window

• Impact of glucagon-like peptide-1 receptor agonist or glucagon-like peptide-1 receptor agonist/glucose-dependent insulinotropic polypeptide receptor agonists after bariatric surgery in the veteran populationopens in new tab/window

• Impact of obesogenic medications on weight loss potential with glucagon-like peptide-1 receptor agonistsopens in new tab/window

• Beyond glucagon-like peptide-1: The promise of polyagonists in metabolic dysfunction–associated steatotic liver disease and metabolic dysfunction–associated steatohepatitis—A systematic review of randomized trials opens in new tab/window